1-7 of 7
Andrew Krivoshik
Close
Sort by
Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Lode J. Swinnen, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2010) 116 (21): 2455.
https://doi.org/10.1182/blood.V116.21.2455.2455
Published: 2010
Journal Articles

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

Brad Kahl, MD, Andrew W Roberts, MBBS, PhD, John F Seymour, MD, Ranjana H. Advani, MD, Daniel Oscar Persky, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2010) 116 (21): 3943.
https://doi.org/10.1182/blood.V116.21.3943.3943
Published: 2010
Journal Articles

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, Owen A O'Connor, MD, PhD, Myron S Czuczman, Ann LaCasce, MD, John Gerecitano, MD, PhD, John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 1711.
https://doi.org/10.1182/blood.V114.22.1711.1711
Published: 2009
Journal Articles

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Andrew W. Roberts, MBBS, PhD, John F Seymour, MB, BS, PhD, FRACP, Jennifer R Brown, MD, PhD, William G Wierda, Thomas J. Kipps, MD, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Hao Xiong, Ph.D., Yue Cui, PhD, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 883.
https://doi.org/10.1182/blood.V114.22.883.883
Published: 2009
Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2374.
https://doi.org/10.1182/blood.V114.22.2374.2374
Published: 2009
Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3177.
https://doi.org/10.1182/blood.V112.11.3177.3177
Published: 2008
Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 2108.
https://doi.org/10.1182/blood.V112.11.2108.2108
Published: 2008